4//SEC Filing
Adda Nathalie 4
Accession 0001062993-22-009836
CIK 0001177648other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 7:54 PM ET
Size
34.7 KB
Accession
0001062993-22-009836
Insider Transaction Report
Form 4
Adda Nathalie
Sr. VP & Chief Medical Officer
Transactions
- Sale
Common Stock
2022-04-04$73.42/sh−9,009$661,441→ 34,982 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-04-01−31,664→ 0 totalExercise: $30.00Exp: 2026-11-18→ Common Stock (31,664 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2022-04-04−16,875→ 13,125 totalExercise: $63.35Exp: 2029-11-18→ Common Stock (16,875 underlying) - Exercise/Conversion
Common Stock
2022-04-01$30.00/sh+31,664$949,920→ 82,646 total - Sale
Common Stock
2022-04-01$71.32/sh−42,260$3,013,983→ 34,982 total - Exercise/Conversion
Common Stock
2022-04-04$43.57/sh+9,625$419,361→ 50,892 total - Exercise/Conversion
Common Stock
2022-04-04$63.35/sh+16,875$1,069,031→ 67,767 total - Sale
Common Stock
2022-04-04$72.65/sh−3,200$232,480→ 43,991 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-04-01−16,000→ 0 totalExercise: $31.42Exp: 2025-11-20→ Common Stock (16,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2022-04-01−2,895→ 6,285 totalExercise: $48.52Exp: 2027-11-17→ Common Stock (2,895 underlying) - Sale
Common Stock
2022-04-04$70.56/sh−2,500$176,400→ 65,267 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-04-04−6,285→ 0 totalExercise: $48.52Exp: 2027-11-17→ Common Stock (6,285 underlying) - Exercise/Conversion
Common Stock
2022-04-01$31.42/sh+16,000$502,720→ 50,982 total - Exercise/Conversion
Common Stock
2022-04-01$48.52/sh+2,895$140,465→ 85,541 total - Sale
Common Stock
2022-04-01$70.75/sh−8,299$587,154→ 77,242 total - Exercise/Conversion
Common Stock
2022-04-04$48.52/sh+6,285$304,948→ 41,267 total - Sale
Common Stock
2022-04-04$71.71/sh−18,076$1,296,230→ 47,191 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-04-04−9,625→ 21,175 totalExercise: $43.57Exp: 2030-11-20→ Common Stock (9,625 underlying)
Footnotes (10)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan.
- [F10]The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019).
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive.
- [F5]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive.
- [F6]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive.
- [F7]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive.
- [F8]100% of the shares subject to the option are fully vested and exercisable.
- [F9]The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020).
Issuer
ENANTA PHARMACEUTICALS INC
CIK 0001177648
Entity typeother
Related Parties
1- filerCIK 0001646976
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 7:54 PM ET
- Size
- 34.7 KB